ISRCTN73030316已完成2 期
A randomised phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive transitional cell carcinoma (TCC) of the urothelium
HS Greater Glasgow and Clyde (UK)0 个研究点目标入组 131 人开始时间: 2012年3月19日最近更新:
适应症
试验速览
- 阶段
- 2 期
- 状态
- 已完成
- 发起方
- 入组人数
- 131
研究概览
简要总结
2017 Results article in https://www.ncbi.nlm.nih.gov/pubmed/28402747 results
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- All
入选标准
- •1. Histologically or cytologically confirmed TCC (bladder, renal pelvis, ureter, urethra), which is locally advanced or metastatic (T4b and/or N1-3 and/or M1). Patients with mixed or differentiation pattern pathology will be permitted entry providing that TCC is a component pathology.
- •2. Progressive disease during or after one prior platinum-based chemotherapy regimen for advanced disease or as peri-operative therapy for muscle-invasive/node positive disease (if completed < 12 months prior to documented disease progression). The regimen must have included either cisplatin or carboplatin. Patients may have had two platinum containing regimens if one of these was given peri-operatively, and provided that there was a chemotherapy-free interval of at least 12 months between completing the 1st course and commencing the second course of chemotherapy. Chemotherapy given during radical radiotherapy as a radiosensitizer will not be considered as a chemotherapy treatment for the purposes of study eligibility.
- •3. Age = 18 years
- •4. Measurable disease by Response Evaluation Criteria In Solid Tumors (RECIST) 1.1
- •5. Adequate organ function as defined by the following criteria:
- •5.1. Total serum bilirubin =1.5 x upper level of normal (ULN)
- •5.2. Serum transaminases <2.5 x ULN. Concomitant elevations of transaminases and bilirubin are not permitted
- •5.3. Creatinine clearance >30ml/min (calculated by Cockcroft Gault equation) or Creatinine =1.5 x ULN
- •5.4. Absolute neutrophil count (ANC) =1500/mm3 without growth factor support
- •5.5. Platelets = 100,000/mm3
- •5.6. Urine protein to creatinine ratio (UPC) < 110 mg/mmol (1g/g) (or total urinary protein < 1g/24hrs)
- •5.7. Activated partial thromboplastin time (APTT) =1.2 x ULN
- •5.8. International normalised ratio (INR) = 1.2
- •6. Signed and dated informed consent indicating that the patient has been informed of all the pertinent aspects of the trial prior to enrolment
- •7. A negative pregnancy test for women of childbearing potential
- •8. Life expectancy of 3 months or more
- •9. Willingness and ability to comply with scheduled visits, treatment plans and laboratory tests and other study procedures
- •10. Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
排除标准
- •1. Congestive heart failure, myocardial infarction, coronary artery bypass graft or thrombotic cerebrovascular event in the previous six months, or ongoing severe or unstable arrhythmia requiring medication. Patients with rate controlled atrial fibrillation are permitted to enter the study
- •2. History of clinically significant bleeding in the 6 months prior to study initiation (including haemoptysis, cerebrovascular bleed or haematemis; patients with haematuria are permitted entry as long as there is no indication for intervention)
- •3. Major surgery or trauma within 28 days prior to first dose of investigational product and/or presence of any unhealed wound, fracture, or ulcer (procedures such as catheter placement not considered to be major surgery)
- •4. Cerebrovascular accident including transient ischemic attack (TIA), pulmonary embolism or deep venous thrombosis (DVT) within the past 6 months. Subjects with recent DVT who have been therapeutically anti-coagulated for at least 6 weeks are eligible.
- •5. History of another malignancy in the last 5 years (other than treated squamous/basal cell skin cancer, treated early stage cervical cancer or treated / biochemically stable, organ confined prostate cancer)
- •6. Ongoing major gastrointestinal disease including unstable inflammatory bowel disease or bleeding peptic ulcer disease
- •7. Known endobronchial lesions which have a high risk of pulmonary haemorrhage
- •8. Previously identified brain, or central nervous system (CNS) metastases at baseline, with the exception of those subjects who have previously-treated CNS metastases (surgery ± radiotherapy, radiosurgery, or gamma knife) and who meet both of the following criteria: are asymptomatic and have no requirement for steroids or enzyme-inducing anticonvulsants in prior 28 days
- •9. Pregnant or breastfeeding. Patients must be surgically sterile or be postmenopausal, or must agree to use effective contraception during the period of therapy. Male patients must be surgically sterile or agree to use effective contraception
- •10. Administration of any investigational drug within 28 days or five half lives, whichever is longer, prior to receiving the first dose of study treatment
- •11. Treatment with any of the following anti-cancer therapies:
- •11.1. Radiation therapy, surgery or tumour embolisation within 14 days prior to the first dose of study medication
- •11.2. Chemotherapy, immunotherapy, biologic therapy, investigational therapy within 28 days or five half-lives of a drug (whichever is longer) prior to the first dose of study medication
- •12. Peripheral neuropathy of grade 2 or more
- •13. Any on-going toxicity from prior anti-cancer therapy that is >Grade 1 and/or that is progressing in severity, except alopecia
- •14. Other severe or uncontrolled systemic disease or evidence of any other significant clinical disorder or lab finding that makes it undesirable for the patient to participate in the study
- •15. Any psychological, familial, sociological or geographical consideration potentially hampering compliance with the study protocol and follow up schedule; those considerations should be discussed with the patient before registration in the trial
- •16. Known Human immunodeficiency v
研究者
相似试验
进行中（未招募）
1 期
PLUTO - (pazopanib versus paclitaxel in relapsed urothelial tumours) A Randomised Phase II study investigating pazopanib vs weekly paclitaxel in relapsed or progressive Transitional Cell Carcinoma (TCC) of the urotheliumEUCTR2011-001841-34-GBHS Greater Glasgow Health Board131
已完成
1 期
Trial of PAZOpanib with or without FOSbretabulin in advanced recurrent ovarian cancerCancerISRCTN30090285The Christie NHS Foundation Trust (UK)33
进行中（未招募）
不适用
A 12-Week Study of Eye Drops to Treat Wet Age-related Macular Degeneration (AMD)Age-related macular degeneration (AMD)MedDRA version: 14.0Level: PTClassification code 10025409Term: Macular degenerationSystem Organ Class: 10015919 - Eye disordersEUCTR2011-000243-24-DEGlaxoSmithKline Research & Development Ltd.30
已完成
2 期
Pazopanib Plus Lapatinib Compared To Lapatinib Alone In Subjects With Inflammatory Breast CancerNeoplasms, BreastNCT00558103GlaxoSmithKline163
进行中（未招募）
2 期
Pazopanib Hydrochloride in Treating Patients With Progressive Carcinoid TumorsForegut Neuroendocrine TumorHindgut Neuroendocrine TumorMetastatic Digestive System Neuroendocrine Tumor G1Metastatic Neuroendocrine TumorMidgut Neuroendocrine Tumor G1Neuroendocrine Tumor G2Recurrent Digestive System Neuroendocrine Tumor G1Regional Digestive System Neuroendocrine Tumor G1NCT01841736National Cancer Institute (NCI)171